title: Past and present perspectives on encapsulating peritoneal sclerosis.
abstract: Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis. The mortality rate for EPS has been high, primarily due to complications related to bowel obstruction. However, recent advances in clinical research have established the pathogenesis, the disease course, and a treatment strategy. Currently, there is consensus on therapy; however, treatment with corticosteroids and tamoxifen should be administered in a timely manner. The final therapeutic option for EPS is surgical enterolysis (adhesiolysis). Moreover, a biocompatible peritoneal dialysis solution has become available for patients worldwide, which may further reduce peritoneal deterioration and EPS risk. These activities have promoted a better understanding of and have prompted countermeasures against EPS. EPS is no longer considered a fatal complication.
authors.affiliation: Tsuchiya General Hospital, Hiroshima, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Kawanishi
authors.forename: Sadanori
authors.initials: S
authors.lastname: Shintaku
authors.forename: Masataka
authors.initials: M
authors.lastname: Banshodani
authors.forename: Shinji
authors.initials: S
authors.lastname: Hashimoto
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D015314:Dialysis Solutions / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D056627:Peritoneal Fibrosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D010538:Peritonitis / Q000150:complications; D011239:Prednisolone / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D018931:Antineoplastic Agents, Hormonal; D015314:Dialysis Solutions; D013629:Tamoxifen; D011239:Prednisolone